Total Payments
$293,594
2024 Payments
$5,559
Companies
11
Transactions
65
Payment Breakdown by Category
Other$218,287 (74.4%)
Consulting$51,196 (17.4%)
Travel$19,187 (6.5%)
Research$3,702 (1.3%)
Food & Beverage$1,221 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $218,287 | 19 | 74.4% |
| Consulting Fee | $51,196 | 12 | 17.4% |
| Travel and Lodging | $19,187 | 8 | 6.5% |
| Unspecified | $3,702 | 5 | 1.3% |
| Food and Beverage | $1,221 | 21 | 0.4% |
Payments by Type
General
$289,891
60 transactions
Research
$3,702
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $190,981 | 4 | $0 (2024) |
| F. Hoffmann-La Roche AG | $25,047 | 23 | $0 (2024) |
| GE HEALTHCARE | $23,796 | 6 | $0 (2021) |
| UCB Biosciences Inc. | $14,982 | 14 | $0 (2018) |
| UCB SA | $12,456 | 8 | $0 (2018) |
| GENZYME CORPORATION | $11,644 | 4 | $0 (2021) |
| Grifols, S.A. | $5,400 | 2 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $3,953 | 1 | $0 (2021) |
| Sunovion Pharmaceuticals Inc. | $3,575 | 1 | $0 (2022) |
| ROCHE DIAGNOSTICS INTERNATIONAL LTD | $1,734 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,559 | 4 | F. Hoffmann-La Roche AG ($5,518) |
| 2023 | $10,127 | 5 | F. Hoffmann-La Roche AG ($8,393) |
| 2022 | $3,575 | 1 | Sunovion Pharmaceuticals Inc. ($3,575) |
| 2021 | $31,965 | 10 | GENZYME CORPORATION ($11,644) |
| 2020 | $15,211 | 4 | GE Healthcare ($11,611) |
| 2019 | $5,593 | 6 | GE HEALTHCARE ($4,800) |
| 2018 | $221,289 | 29 | Eli Lilly and Company ($190,941) |
| 2017 | $274.08 | 6 | F. Hoffmann-La Roche AG ($156.08) |
All Payment Transactions
65 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/14/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| 10/01/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $2,118.34 | Research |
| Study: Phase II study in early stage Parkinson s Disease Patients | ||||||
| 01/18/2024 | Eli Lilly and Company | AMYVID (Drug) | Food and Beverage | In-kind items and services | $40.30 | General |
| Category: Neuroscience | ||||||
| 09/01/2023 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $6,900.00 | General |
| 08/28/2023 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $1,380.00 | General |
| 08/28/2023 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $40.60 | General |
| 03/30/2023 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $72.85 | General |
| 02/13/2023 | ROCHE DIAGNOSTICS INTERNATIONAL LTD | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,734.00 | General |
| 02/14/2022 | Sunovion Pharmaceuticals Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,575.00 | General |
| 12/15/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $3,952.50 | General |
| 09/19/2021 | GENZYME CORPORATION | — | — | In-kind items and services | $250.00 | Research |
| Study: Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant. | ||||||
| 09/17/2021 | GENZYME CORPORATION | — | — | In-kind items and services | $500.00 | Research |
| Study: Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant. | ||||||
| 07/19/2021 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $584.08 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015 PRX002 IN PARTICIPANTS WITH EARLY PARKINSON S DISEASE WITH A 52-WEEK BLINDED EXTENSION PASADENA | ||||||
| 06/14/2021 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $10,643.75 | General |
| 03/09/2021 | GENZYME CORPORATION | — | — | In-kind items and services | $250.00 | Research |
| Study: Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant. | ||||||
| 03/05/2021 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 01/19/2021 | Grifols, S.A. | — | Consulting Fee | Cash or cash equivalent | $3,400.00 | General |
| 01/19/2021 | Grifols, S.A. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 01/05/2021 | GE HEALTHCARE | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,385.00 | General |
| 11/02/2020 | GE Healthcare | — | Travel and Lodging | Cash or cash equivalent | $9,078.50 | General |
| 04/07/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| Category: None | ||||||
| 03/03/2020 | GE HEALTHCARE | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,688.00 | General |
| 03/03/2020 | GE HEALTHCARE | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $844.00 | General |
| 09/02/2019 | GE HEALTHCARE | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase II study in early stage Parkinson s Disease Patients | F. Hoffmann-La Roche AG | $2,118 | 1 |
| Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant. | GENZYME CORPORATION | $1,000 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015 PRX002 IN PARTICIPANTS WITH EARLY PARKINSON S DISEASE WITH A 52-WEEK BLINDED EXTENSION PASADENA | F. Hoffmann-La Roche AG | $584.08 | 1 |
About Dr. Kenneth Marek, MD
Dr. Kenneth Marek, MD is a Neurology healthcare provider based in New Haven, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1467543728.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kenneth Marek, MD has received a total of $293,594 in payments from pharmaceutical and medical device companies, with $5,559 received in 2024. These payments were reported across 65 transactions from 11 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($218,287).
Ad
Practice Information
- Specialty Neurology
- Location New Haven, CT
- Active Since 09/28/2006
- Last Updated 07/08/2007
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1467543728
Products in Payments
- Non-Covered Product (Drug) $4,554
- AMYVID (Drug) $40.30
- Radicava (Drug) $27.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in New Haven
Sharon Stoll, D.o, D.O
Neurology — Payments: $782,631
Neurology $782,631
Dr. David Russell, M.d., Ph.d, M.D., PH.D
Neurology — Payments: $390,295
Neurology $390,295
David Hafler, Md, MD
Neurology — Payments: $133,003
Neurology $133,003
Stephen Waxman, Md, MD
Neurology — Payments: $125,575
Neurology $125,575
Imran Quraishi, M.d., Ph.d, M.D., PH.D
Neurology — Payments: $107,014
Neurology $107,014
Dr. Daniel Dicapua, Md, MD
Neurology — Payments: $81,404
Neurology $81,404